According to literature data, both high tumor expression and elevated serum levels of YKL-40 are associated with poor outcomes in CRC patients, i.e., shorter overall survival and progression-free survival [65], which were not analyzed in our research. The gene discussed is CHI3L1; the disease is neoplasm.